Stay updated on Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov page’s site revision identifier was updated from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check9 days agoChange DetectedThe page displays the completed BERENICE phase 2 breast cancer study record, including its treatment arms, eligibility criteria, locations, and safety and efficacy outcome measures.SummaryDifference100%

- Check16 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedAn NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision number changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study record page now shows a 403 Forbidden error with a header and a Home button, replacing the detailed study content and location information. Users can no longer access the trial details from this page.SummaryDifference19%

Stay in the know with updates to Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial page.